Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ChatGPT spot cancer cells as well as a pathologist?

NCT ID NCT07228689

Diagnosis Sponsor: Orlando Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study is testing whether an AI tool (ChatGPT) can accurately identify abnormal cells in biopsy samples taken during an endoscopic ultrasound. About 136 adults with solid masses in the digestive tract will have their biopsy images reviewed by both the AI and expert pathologists. The goal is to see if AI can provide a fast, reliable on-the-spot diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ChatGPT artificial intelligence platform
What this could lead to
If successful, this could show that AI can help doctors quickly and accurately analyze biopsy samples during procedures, potentially speeding up diagnosis.
What could go wrong
This is a relatively small, single-center study. AI may not be as accurate as human experts, and results may not apply to other settings or types of samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

136 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 18 years or greater, undergoing EUS-guided fine needle biopsy of solid mass lesions in the gastrointestinal tract.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years old or greater * Patients undergoing EUS-guided fine needle biopsy of solid mass lesions in the gastrointestinal tract Exclusion Criteria: * Age less than 18 years * Patients not undergoing sampling of solid mass lesions at EUS * Patients with cystic lesions in the gastrointestinal tract

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal neoplasm Mass lesion

Contacts and locations

Locations

  • Orlando Health Digestive Health Institute

    Orlando, Florida, 32806, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.